Jürgen Behr, ERS 2022: Impact of Pirfenidone on the Treatment Paradigm for Advanced IPF
Idiopathic pulmonary fibrosis (IPF) is a rare, progressive lung disease, in which the lungs become scarred making breathing difficult and most patients with IPF progress to advanced disease. It was a pleasure to talk with Prof. Jürgen Behr (Ludwig-Maximilians-University of Munich, Munich, Germany) around the unmet needs in the treatment of advanced IPF and the impact of pirfenidone on the treatment paradigm in this indication.
The abstract ‘Efficacy of pirfenidone in patients with advanced IPF.’ (Abstract number: PA1936) was presented at ERS 2022, 4–6 September, 2022.
Questions
- What has been the impact of pirfenidone on the treatment of IPF? (1:35)
- What are the unmet needs in the treatment of advanced IPF? (3:02)
Disclosures: Jürgen Behr discloses consulting for Biogen, Boehringer-Ingelheim, Bristol-Myer-Squibbs, Ferrer, Galapagos, Pliant, Roche and Sanofi/Genzyme; discloses receiving grant/ research support from DFG and BMBF; serving on advisory boards for Biogen, Boehringer-Ingelheim, Bristol-Myer-Squibbs, Ferrer, Galapagos, Pliant, Roche and Sanofi/Genzyme; receiving honoraria from Biogen, Boehringer-Ingelheim, Bristol-Myer-Squibbs, Ferrer, Galapagos, Pliant, Roche and Sanofi/Genzyme; participating in speaker’s bureaus for Astra-Zeneca, Boehringer-Ingelheim, Ferrer, MSD, Novartis and Roche.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ERS meeting 2022.
